News

June 13, 2026

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

June 12, 2026

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

May 29, 2026

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

May 28, 2026

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

May 26, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 12, 2026

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

May 6, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

May 5, 2026

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 4, 2026

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

May 1, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity